Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of
thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge …

Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

Background—Patients with diabetes mellitus (DM) are at high risk for recurrent
cardiovascular events after acute coronary syndromes, in part because of increased platelet …

Cardiovascular disease, particularly coronary artery dis-ease resulting from accelerated
atherosclerosis, is the leading cause of morbidity and mortality in patients with diabetes …

Currently, clopidogrel is recommended for treatment of patients with acute coronary
syndrome and/or percutaneous coronary intervention. However, the delayed onset of the …

Objectives: The aim of this study was to evaluate the relative impact of demographic and
clinical variables versus the cytochrome P450 2C19 (CYP2C19) polymorphism on …

Context: The safety of insulin in the treatment of type 2 diabetes mellitus (T2DM) has recently
undergone scrutiny. Objective: The objective of the study was to characterize the risk of …

Patients with diabetes mellitus have an increased prevalence of vascular disease.
Pathologic thrombosis associated with atherosclerotic plaque rupture is a major cause of …

Background—After treatment with clopidogrel, patients with type 2 diabetes mellitus (T2DM)
have reduced platelet inhibition compared with patients who are not diabetic. Whether …

Objectives: This study sought to determine the prognostic implications of high platelet
reactivity (HPR) assessed in type 2 diabetes mellitus (T2DM) patients while in their steady …